Reaffirms company’s vision for priority introduction of the dengue vaccine in endemic countries globally
Sanofi Pasteur, the vaccines division of Sanofi, announced that the Philippines have granted marketing approval to Dengvaxia, making it the first vaccine to be licensed for the prevention of dengue in Asia.
The Philippines’ Food and Drug Administration approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue types in individuals from nine to 45 years of age living in endemic areas.
Dengue is a major public health priority in tropical and subtropical countries in Asia and Latin America. Sanofi Pasteur is introducing Dengvaxia first in these countries where the vaccine has the greatest potential to reduce dengue burden globally and help to achieve the World Health Organization’s goal to reduce dengue mortality by 50 per cent and morbidity by 25 per cent by 2020 in endemic countries. Sanofi Pasteur enrolled over 40,000 participants in extensive safety and clinical efficacy studies conducted mainly in endemic countries and built a dedicated vaccine production facility in France to secure adequate quality and quantity supply of the vaccine to meet endemic country demand upon introduction.